Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + Envafolimab Adjuvant Therapy for High-Risk Recurrent HCC
NCT06498622Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jul 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Nanobodies (VHH), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and envafolimab in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Recurrence-Free Survival at 24 months. Started Jul 2024; status: recruiting.
02
Drugs
donafenibenvafolimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06498622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06498622.